Multiple myeloma (MM), a clonal plasma cell malignancy accounts for approximately 10 per cent of haematologic malignancies. Compared to industrialized nations, myeloma occurs a decade earlier in India, at a median age of 55 yr[@ref1]. Present management of myeloma patients includes novel agents (immunomodulators - thalidomide, lenalidomide, proteasome inhibitors - bortezomib)-based initial (induction) therapy for 4-6 months followed by autologous stem cell transplantation (ASCT) in patients aged ≤65-70 yr without major co-morbidities. This is followed by low-dose maintenance therapy with either lenalidomide or thalidomide or bortezomib for two years. For elderly patients (≥65-70 yr) or those not suitable for ASCT induction, therapy is given for 6-9 months followed by maintenance therapy. The ASCT is an integral component of myeloma management and has contributed to survival improvement in the past two decades[@ref2]. Initial transplant studies have used conventional chemotherapy before ASCT. A number of randomized studies[@ref3][@ref4][@ref5][@ref6][@ref7] and meta-analyses[@ref8] have confirmed that ASCT is associated with deepening of response rate and improved progression-free survival (PFS) in most and overall survival (OS) in some studies compared to conventional cytotoxic chemotherapy. Subsequently, these results were confirmed in recent randomized studies[@ref9][@ref10][@ref11][@ref12][@ref13][@ref14] using novel agents-based induction before ASCT further augmenting responses with improvement in survival. While enough experience with ASCT for long-term outcome has been reported from developed countries[@ref15][@ref16][@ref17][@ref18][@ref19][@ref20], comprehensive information from resource-limited setting like ours, on the long-term outcome following transplant is limited[@ref21]. We have reported our initial experience for MM patients transplanted till the year 2014[@ref22]. Here we report an updated follow up with long-term outcome on patients with MM transplanted between 1995 and 2016 as well as comprehensive analysis of prognostic factors associated with long-term survival.

Material & Methods {#sec1-2}
==================

The data on 349 consecutive MM patients, who underwent ASCT at Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIIMS), New Delhi, India, between 1995 and December 2016 were analysed. The study was approved by the Ethics Committee of AIIMS. The patients\' characteristics are shown in [Table I](#T1){ref-type="table"}. The median age was 52 yr ranging from 29 to 68 yr; 236 (67.6%) were males, 34.7 per cent had international staging system (ISS) Stage III disease and 24.4 per cent had Stage IIIB by Durie-Salmon staging (DSS). Eighty one (23.6%) patients had light chain myeloma, 251 (71.9%) received novel agents for induction, 75 (21.5%) received \[vincristine, adriamycin and dexamethasone (VAD) as continuous infusion\] and the remaining 23 (6.6%) received alkylating agents-based induction regimens. One hundred twenty five patients (36%) had received more than one induction regimen before transplant. Median interval from diagnosis to transplant was 10 months, ranging from 2 to 128 months.

###### 

Characteristics of the patients included in the study

  Variable                                 All patients (n=349), n (%)
  ---------------------------------------- -----------------------------
  Age (yr)                                 
  Median                                   52
  Range                                    29-68
  Gender                                   
  Male                                     236 (67.6)
  Female                                   113 (32.4)
  International staging system (ISS)       
  I                                        103 (30.0)
  II                                       121 (35.3)
  III                                      119 (34.7)
  Durie-Salmon staging system (DSS)        
  ≤IIIA                                    263 (75.6)
  IIIB                                     85 (24.4)
  Ig type (n=342)                          
  IgG                                      204 (59.6)
  IgA                                      57 (16.7)
  Light chain                              81 (23.7)
  Extramedullary disease (EMD)             
  Yes                                      80 (22.9)
  No                                       229 (77.1)
  Haemoglobin (g/dl)                       
  ≤10                                      201 (57.6)
  \>10                                     148 (42.4)
  Serum albumin (g/dl)                     
  \<3.5                                    140 (40.1)
  ≥3.5                                     59.9 (59.9)
  BM-PC% (n=348)                           
  \<40                                     180 (51.7)
  ≥40                                      168 (48.3)
  Calcium (mg/dl) (n=324)                  
  ≤11.4                                    296 (91.4)
  ≥11.5                                    28 (8.6)
  eGFR (ml/min)                            
  \<40                                     86 (24.6)
  ≥40                                      263 (75.4)
  Induction treatment                      
  Novel agents                             251 (71.9)
  VAD                                      75 (21.5)
  Alkylating agents                        23 (6.6)
  Pre-transplant status                    
  Sensitive (CR+VGPR+PR)                   291 (83.4)
  Resistant (stable+progressive disease)   58 (16.6)
  Interval (months)                        
  ≤12                                      220 (63.0)
  \>12                                     129 (37.0)
  Induction regimen (n=348)                
  One line                                 223 (64.1)
  \>One line                               125 (35.9)

BM-PC, bone marrow plasma cell; eGFR, estimated glomerular filtration rate; VAD, vincristine, adriamycin and dexamethasone; Ig, immunoglobulin; CR, complete response; PR, partial response; VGPR, very good partial response

*Novel agents-based induction therapy*: Among 251 patients, 178 (71.9%) had received two drug combination (thalidomide+dexamethasone, n=92, lenalidomide+dexamethasone, n=54 and bortezomib+dexamethasone, n=32), 71 (20.3%) patients received three-drug combination \[VTd (bortezomib+thalidomide+dexamethasone) n=23, VRd (bortezomib+thalidomide+ dexamethasone) n=23, VCd (bortezomib+cyclophosphamide+ dexamethasone) n=21, PAd (liposomal doxorubicin, bortezomib and dexamethasone) n=1 and 3 patients received thalidomide-based combinations\]. Two patients received four-drug VTCd (bortezomib+thalidomide+cyclophosphamide+dexamethasone)-based combination.

*Transplant protocol*: Granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood stem cells (CD34+ ≥2×10[@ref6]/kg) were collected. For conditioning, high-dose melphalan (200 mg/m^2^) was administered; patients with renal impairment (RI) received melphalan[@ref23] in dose of 140-150 mg/m^2^. This was followed by stem cells infusion. Fifty six patients received stem cells cryopreserved at −80°C, the remaining 293 patients received stem cells stored at 4°C. Transplant response evaluation was done on day 100 ± one week as per European Group for Blood and Marrow Transplant (EBMT) criteria[@ref24]. Patients were advised maintenance therapy using low-dose thalidomide (50 mg daily) or lenalidomide (5-10 mg/day) for 21 days every month or injection bortezomib 2 mg subcutaneously twice a month. In addition, patients with adequate estimated glomerular filtration rate (eGFR) (≥60 ml/min)[@ref23][@ref25] also received injection zoledronic acid once in three months for first two years then once in six months indefinitely along with calcium and vitamin D supplement.

*Statistical analysis*: An intention-to-treat analysis was done. Descriptive statistics (median and range) were calculated for all variables. Response to transplant was defined as per the EBMT criteria[@ref24]. The prognostic factors for response to transplant were analyzed by Pearson Chi-square test and binary logistic regression analysis. OS was defined as the time from date of transplant until death or date of censor (December 31, 2017). PFS was calculated from date of transplant to disease progression or death (regardless of the cause of death). Survival curves were plotted according to the method of Kaplan and Meier[@ref26] and were compared by the log-rank test. The prognostic factors for survival were analyzed by Cox regression analysis. Analysis was carried out using SPSS-16 statistical software (IBM, Atlanta, USA). The median follow up for the whole group was 73 months (range 12.50-292 months).

Results {#sec1-3}
=======

A total of 213 (61%) patients achieved complete response (CR), 62 (17.8%) had very good partial response (VGPR), 42 (12.0%) partial response (PR) and 14 (4.0%) patients had stable disease. Eighteen (5.2%) patients died of transplant-related complications (before day 100).

*Post-transplant complete response (CR) rate according to pre-transplant status*: Among patients with pre-transplant VGPR, 70 (42/60) per cent achieved CR post-transplant, CR rate was 45.5 per cent for those in PR, 23 per cent for those with stable disease and 12.5 per cent for patients with progressive disease pre-transplant ([Table II](#T2){ref-type="table"}).

###### 

Response to transplant in patients

  Pre-transplant        Number of patients, n (%)   Post-transplant                                      
  --------------------- --------------------------- ----------------- ----------- ----------- ---------- ----------
  CR                    119 (34.1)                  110 (92.4)        4           \-          1          4
  VGPR                  60 (17.2)                   42 (70.0)         14          1           \-         3
  PR                    112 (32.1)                  51 (45.5)         30          20          6          5
  Stable                26 (7.4)                    6 (23.1)          10          7           \-         3
  Progressive disease   32 (9.2)                    4 (12.5)          4           14          7          3
  Total, n (%)          349                         213 (61.0)        62 (17.8)   42 (12.0)   14 (4.0)   18 (5.2)

Abbreviations are as given in [Table I](#T1){ref-type="table"}

*Post-transplant response rate according to primary induction regimen*: Overall response rate (CR+VGPR+PR) was higher for patients who received novel agents (92.8%) versus VAD (92.0%) versus alkylating agents (65.2%), *P*\<0.001 \[novel agents vs. VAD (*P*\<0.02), novel agents vs. alkylating agents (*P*\<0.001), VAD versus alkylating agents, (*P*\<0.01)\]. Corresponding CR rates were 68.1 per cent versus 48.0 per cent versus 26.1 per cent (*P*\<0.001). Among novel agents, there was no significant difference in the response rate between those who received doublet (n=178) versus triplet (n=73) (CR 68.8 vs. 71.2%, P=0.223).

*Predictors of transplant response*: Patients with pre-transplant chemosensitive disease (CR+VGPR+PR, *P*\<0.001), induction with novel agents (*P*\<0.001), transplant in first remission compared to those who underwent transplant after salvage induction (*P*\<0.001), those who received one line of induction therapy (*P*\<0.001) and serum albumin \>3.5 g/dl at diagnosis (*P*\<0.02) had higher probability of response to transplant.

*Day 100 transplant-related mortality (TRM)*: Eighteen (5.2%) patients died before day 100 due to transplant-related complications. Low haemoglobin (Hb) (\<10 g/dl) (*P*\<0.05), low serum albumin (\<3.5 g/dl) (*P*\<0.005), low eGFR \<40 ml/min[@ref25], (*P*\<0.01), Durie-Salmon Stage IIIB (*P*\<0.01) and transplant during second or subsequent remission after salvage induction (*P*\<0.05) were predictors of higher mortality. Transplant-related mortality (TRM) was higher for patients transplanted before 2005 compared to those transplanted between 2006-2010 and 2011-2016; 9/81 (11.1%) versus 3/80 (3.8%) versus 6/188 (3.2%), *P*\<0.02 ([Table III](#T3){ref-type="table"}).

###### 

Predictors of transplant related mortality

  Factor                                                         n         Day 100 mortality, n (%)   *P* value
  -------------------------------------------------------------- --------- -------------------------- -----------
  Age (yr)                                                                                            
  ≤52                                                            177       11 (6.2)                   0.254
  \>52                                                           172       7 (4.1)                    
  Gender                                                                                              
  Male                                                           236       9 (3.8)                    0.08
  Female                                                         113       9 (8.0)                    
  International staging system (ISS) (n=343)                                                          
  I                                                              103       2 (1.9)                    0.229
  II                                                             121       7 (5.8)                    
  III                                                            119       8 (6.7)                    
  Durie-Salmon staging system (DSS) (n=348)                                                           
  ≤IIIA                                                          263       9 (3.4)                    0.01
  IIIB                                                           85        9 (10.6)                   
  Extramedullary disease (EMD)                                                                        
  Yes                                                            80        5 (6.3)                    0.39
  No                                                             269       13 (4.8)                   
  Induction therapy                                                                                   
  Novel agents                                                   251       10 (4.0)                   0.13
  VAD                                                            75        5 (6.7)                    
  Alkylating agents                                              23        3 (13.0)                   
  Number of regimens                                                                                  
  One line                                                       223       8 (3.6)                    0.06
  \>One line                                                     125       10 (8.0)                   
  Myeloma type (n=342)                                                                                
  IgG                                                            204       15 (7.4)                   0.09
  IgA                                                            57        2 (3.5)                    
  K+L                                                            81        1 (1.2)                    
  Interval (months)                                                                                   
  ≤12                                                            220       10 (4.54)                  0.33
  \>12                                                           129       8 (6.2)                    
  Haemoglobin (g/dl)                                                                                  
  ≤10                                                            201       14 (7.0)                   0.05
  \>10                                                           148       4 (2.7)                    
  Serum albumin (g/dl)                                                                                
  \<3.5                                                          140       13 (9.3)                   0.005
  ≥3.5                                                           209       5 (2.4)                    
  BM-PC% (n=348)                                                                                      
  ≤40                                                            180       10 (5.6)                   0.46
  \>40                                                           168       8 (4.8)                    
  Baseline eGFR (ml/min)                                                                              
  ≤40                                                            86        9 (10.5)                   0.01
  \>40                                                           263       9 (3.4)                    
  Serum calcium (n=324) (mg/dl)                                                                       
  ≥11.5                                                          28        3 (10.7)                   0.13
  \<11.5                                                         296       12 (4.1)                   
  Pre-transplant status                                                                               
  Sensitive (CR+VGPR+PR)                                         291       13 (4.5)                   0.16
  Resistant (stable+progressive disease)                         58        5 (8.6)                    
  Transplant in first remission versus during second remission   245 104   9 (3.7) 9 (8.7)            0.05
  Melphalan dose (n=347) (mg/m^2^)                                                                    
  ≤140                                                           35        2 (5.7)                    0.56
  \>140                                                          312       16 (5.1)                   
  Year of transplant                                                                                  
  Till 2005                                                      81        9 (11.1)                   0.02
  2006-2010                                                      80        3 (3.8)                    
  2011-2016                                                      188       6 (3.2)                    

*P* value calculated by Chi-square test. Abbreviations are as given in [Table I](#T1){ref-type="table"}

*Survival*: Median OS and PFS from date of transplant for all patients was 90 months \[95% confidence interval (CI) 70.8-109.2\] and 41 months (95% CI 33.0-49.03), respectively (Figs. [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). The estimated OS and PFS at 2, 5, 10 and 15 yr was 81.4 versus 64.6 per cent, 60.8 versus 40.6, 40.4 versus 28.2 per cent and 17.7 versus 15.6 per cent, respectively.

![Overall survival for patients from date of transplant.](IJMR-149-730-g001){#F1}

![Progression free survival for patients from date of transplant.](IJMR-149-730-g002){#F2}

*Predictors of overall survival (OS): Univariate analysis*: Patients with ISS Stages I and II (*P*\<0.001), Durie-Salmon Stages IIIA (*P*\<0.001), absence of extramedullary disease (*P*\<0.001), serum albumin (≥3.5 g/dl) (*P*\<0.001), eGFR at diagnosis (≥40 ml/min) (*P*\<0.001), pre-transplant chemosensitive disease (*P*\<0.001), novel agents-based induction (*P*\<0.004), achievement of CR post-transplant (*P*\<0.001), transplant within 12 months of diagnosis (*P*\<0.001) and those who had received one line of induction therapy (*P*\<0.001) and patients with transplant in first remission had better OS ([Table IV](#T4){ref-type="table"}).

###### 

Predictors of overall survival: Univariate analysis

  Factor                                   Variable                 No. of patients   Median OS     95% CI                            *P* value
  ---------------------------------------- ------------------------ ----------------- ------------- --------------------------------- -----------
  Age (yr)                                 ≤52                      177               90.0          52.2-127.8                        0.897
  \>52                                     172                      85.5              65.3-105.7                                      
  Gender                                   M                        236               91            65.5116.4                         0.229
  F                                        113                      85.5              33.5-137.5                                      
  ISS (n=343)                              I                        103               127           73.9-180.0                        0.001
  II                                       121                      91.50             76.8-106.2    I Vs II=0.31                      
  III                                      119                      59.0              44.8-73.2     II Vs III-0.006 I Vs III=0.0002   
  DSS (n=348)                              ≤IIIA                    263               97.0          69.3-125.0                        0.001
  IIIB                                     85                       60.5              43.7-77.3                                       
  EMD                                      Yes                      80                42.5          19.5-65.5                         0.001
  No                                       269                      102.0             80.6-123.4                                      
  Albumin (g/dl)                           ≥3.5                     140               59.0          37.6-80.4                         0.001
  \<3.5                                    209                      114.5             75.1-154.0                                      
  Hb (g/dl)                                ≤10                      201               71.5          41.2-101.8                        0.07
  \>10                                     148                      97.0              58.7-135.3                                      
  BM-PC% (n=348)                           ≤40                      180               100.0         57.9-142.1                        0.260
  \>40                                     168                      79.0              56.4-101.6                                      
  Ig type (n=342)                          IgG                      204               96.0          66.8-125.2                        0.48
  IgA                                      57                       79.0              51.2-106.8                                      
  K + L                                    81                       83.5              44.2-122.7                                      
  Induction                                Novel                    251               91.5          67.4-115.6                        0.004
  VAD                                      75                       85.5              54.4-116.6                                      
  Alkylating agents                        23                       24.0              9.1-39.0                                        
  Regimen (n=348)                          One line                 223               124.5         87.7-161.3                        0.001
  \>One line                               125                      50.5              35.8-65.2                                       
  eGFR (ml/min)                            \<40                     86                60.5          43.5-77.5                         0.001
  ≥40                                      263                      97.0              69.93-124.1                                     
  Pre-transplant status                    Sensitive (CR+VGPR+PR)   291               102.0         82.9-121.1                        0.001
  Resistant (stable+progressive disease)   58                       48.0              29.2-66.8                                       
  Interval diagnosis-transplant (months)   ≤12                      220               106.0         78.9-133.0                        0.001
  \>12                                     129                      59.0              41.9-76.0                                       
  CD34+ cells (×10[@ref6]/kg)              ≤4.0                     240               91.5          68.9-114.1                        0.10
  \>4                                      68                       106.0             58.1-153.9                                      
  Post-transplant response                 CR                       213               150.0         123.5-184.8                       0.001
  Others                                   136                      32.0              22.6-41.4                                       
  Transplant in remission                  1^st^ remission          245               125           96.6-154.4                        0.001
  Post-salvage                             104                      37                23.0-51.0                                       

ISS, international staging system; DSS, Durie-Salmon staging system; BM-PC, bone marrow plasma cell; EMD, extra-medullary disease; Hb, haemoglobin; VAD, vincristine, adriamycin and dexamethasone; Ig, immunoglobulin; OS, overall survival. Abbreviations are as given in [Table I](#T1){ref-type="table"}

*Predictors of progression-free survival (PFS)*: Patients with DSS Stage IIIA (*P*\<0.02), transplant within 12 months of diagnosis (*P*\<0.03), novel agents-based induction (*P*\<0.001), pre-transplant chemosensitive disease (*P*\<0.001) and achievement of CR post-transplant (*P*\<0.001) were associated with superior PFS. The presence of extramedullary disease (*P*\<0.001), transplant in second or subsequent remission post-salvage therapy (*P*\<0.001), Hb ≤10 g/dl (*P*\<0.05) and albumin \<3.5 g/dl (*P*\<0.001) were predictors of inferior PFS ([Table V](#T5){ref-type="table"}).

###### 

Predictors of progression-free survival: Univariate analysis

  Factor                                   Variable                 Median PFS   95% CI       *P* value
  ---------------------------------------- ------------------------ ------------ ------------ -----------
  Age (yr)                                 ≤52                      36.0         25.5-46.4    0.817
  \>52                                     44.0                     29.8-58.1                 
  Gender                                   Male                     45.5         35.4-55.6    0.179
  Female                                   35.0                     24.2-45.8                 
  ISS                                      I                        53.0         16.7-89.3    0.070
  II                                       44.0                     34.8-53.1                 
  III                                      30.0                     20.3-39.5                 
  DSS                                      ≤IIIA                    44.0         33.8-54.2    0.02
  IIIB                                     30.0                     15.9-44.1                 
  EMD                                      Yes                      24.0         15.5-22.5    0.001
  No                                       46.0                     36.0-56.0                 
  Albumin (g/dl)                           ≥3.5                     28.0         18.3-37.7    0.001
  \<3.5                                    52.0                     27.5-76.5                 
  Hb (g/dl)                                ≤10                      34.0         24.9-43.1    0.05
  \>10                                     51.0                     38.2-64.0                 
  BM PC%                                   ≤40                      50.0         21.8-78.2    0.211
  \>40                                     35.0                     26.2-43.8                 
  Ig type                                  IgG                      41.0         28.2-53.8    0.571
  IgA                                      41.0                     33.1-48.9                 
  K + L                                    38.0                     0.44-75.6                 
  Induction                                Novel                    50.0         35.1-64.8    0.001
  VAD                                      31.0                     16.9-45.1                 
  Alkylating agents                        18.0                     11.7-24.3                 
  Regimen                                  One line                 62.0         34.0-90.0    0.001
  \>One line                               22.0                     18.2-25.2                 
  Pre-transplant status                    Sensitive (CR+VGPR+PR)   51.0         38.5-63.5    0.001
  Resistant (stable+progressive disease)   18.0                     12.8-23.2                 
  Interval diagnosis-transplant (months)   ≤12                      48.0         38.3-57.7    0.03
  \>12                                     28.0                     19.7-36.3                 
  CD34 + cells (×10[@ref6]/kg)             ≤4                       39.0         31.2-46.7    0.24
  \>4                                      51.0                     30.1-71.9                 
  Post-transplant response                 CR                       91.0         60.9-121.0   0.001
  Others                                   16.0                     14.5-17.5                 
  Transplant remission                     1^st^ remission          62.0         41.0-82.9    0.001
  Post-salvage                             20.0                     14.8-25.2                 

Abbreviations are as given in [Table IV](#T4){ref-type="table"}

*Multivariate analysis for overall and progression-free survival*: Serum albumin (\<3.5 g/dl), presence of extramedullary disease and ISS Stage III were predictors for inferior OS. Achievement of CR post-transplant and transplant in first remission were predictors for superior OS. Achievement of CR post-transplant and transplant in first remission were predictors for superior PFS ([Table VI](#T6){ref-type="table"}).

###### 

Multivariate analysis for overall and progression free survival

  Variable                                 *P* value   Hazard   95% CI
  ---------------------------------------- ----------- -------- -------------
  OS                                                            
  Serum albumin                            0.01        1.620    1.12-2.336
  EMD                                      0.005       1.835    1.207-2.79
  Stage ISS I + II versus III              0.009       0.598    0.405-0.881
  Primary versus post-salvage transplant   0.001       0.502    0.342-0.737
  Post-transplant CR                       0.001       0.382    0.262-0.556
                                                                
  **PFS**                                                       
                                                                
  Primary versus post-salvage transplant   0.017       0.652    0.459-0.926
  Post-transplant CR                       0.001       0.245    0.180-0.334

Abbreviations are as given in [Table IV](#T4){ref-type="table"}

*Current status*: In a follow up of patients done in 2018, 184 of 349 patients (52.7%) were alive; 134 (38.4%) progression free, 25 (7.2%) with disease and were on salvage therapy, 17 (4.9%), were in second CR after salvage therapy and eight (2.3%) patients had low level serum M spike, \<1 g/dl (MGUS like). A total of 164 (47.1%) patients died; these included -- 18 (5.2%) deaths before day 100 (TRM), 129 (37.0%) due to progressive disease and its complications and 17 patients (4.9%) due to unrelated reasons. Causes included second malignancy in five (myelodysplastic syndrome -- 1, acute myeloid leukaemia -- 1, renal cell cancer -- 1, hepatocellular carcinoma -- 1, carcinoma tongue -- 1), dengue fever in two, coronary artery disease in six, cerebral haemorrhage, Alzheimer\'s disease, acute graft versus host disease and ventilator-associated complications in one patient each. Status was unknown for one patient.

Discussion {#sec1-4}
==========

Post-transplant high CR rate, higher median OS (90 months) and PFS (41 months) with 10 yr survival rate of 40.4 and 28.2 per cent, respectively, are important findings in the present study. More than one-third of patients had high-risk disease at diagnosis. Post-transplant overall response rate (90.8%) was high in the present study; this was similar to earlier observations[@ref13][@ref14][@ref22]. Conversion to post-transplant CR from pre-transplant response - very good PR (70%), PR (45.5%) and 23 per cent CR in those with stable disease reflected contribution by transplant in augmenting the response already achieved with pre-transplant therapy. Post-transplant CR rate was not significantly different between doublet versus triplet regimen. At present, it is recommended to use triplet (three-drug combinations)[@ref2][@ref13]; however, there is no direct comparison between different triplets being used currently (VTD vs. VRD vs. VCD). There is also suggestion that four cycles of induction may be adequate and more may not be better[@ref27].

A median OS and PFS of 90 and 41 months\\in our study is similar to earlier studies[@ref15][@ref16][@ref17][@ref18][@ref19][@ref20] reporting long-term transplant results. An estimated OS at 10 and 15 yr (40.4 and 17.7%, respectively) indicated prolonged survival in some patients. Similarly, PFS of 15.6 per cent at 15 yr was indicative of a functional cure in a subgroup of patients. A long-term follow up is still needed in the absence of a plateau in survival curve[@ref28]. Achievement of CR post-transplant and transplant in first remission were important predictors of OS and PFS. For those who achieved CR, median OS was 150 months (95% CI 123.5-184.8), significantly higher to those with VGPR and PR. These findings were similar to earlier studies[@ref29]. Achievement of CR post-transplant has been identified as an important marker of long-term survival and is considered to be a desirable goal. Recent studies have suggested that achievement of \'nil\' minimal residual disease (MRD) status on multiparameter flow cytometry is a better surrogate marker of long-term survival[@ref30].

In the present study, \'day +100\' TRM was 5.2 per cent; this was higher than the current standard of one per cent or less[@ref13]. Important predictive factors of higher mortality were low serum albumin (\<3.5 g/dl) and low estimated GFR (\<40 ml/min) at diagnosis and transplant in second or subsequent remission. A reduction in TRM could be due to a combined effect of better case selection, better supportive care and use of novel agents leading to higher response rates including CR which resulted in better depth of response post-transplant and better PFS and OS. Five patients (5/18) had graft failure; three of these had CD34+ stem cells \<2 million and two patients had 3.38 and 6.70 million, respectively. In the present study, 56 patients received stem cells cryopreserved at −80°C, the remaining 293 patients received stem cells kept at 4°C. There was no difference in outcome OS and PFS in the two groups. This was consistent with earlier observations from our centre[@ref22] and those reported recently[@ref31]. No difference was observed in outcome of patients who received ≤4 million CD34+ stem cells or more.

Lack of cytogenetic/FISH (florescent *in situ* hybridization) data was an important limitation of the present study for most patients.

In conclusion, the findings of the present study showed higher response rate to transplant translating into improved progression free and overall survival. Reducing TRM to \<1 per cent and further improvement in CR rates and long-term survival remain desirable goals in future studies.
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